Litigation Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2018)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-05-07 |
Court | District Court, D. Delaware | Date Terminated | 2022-12-14 |
Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
Jury Demand | None | Referred To | |
Parties | APOTEX CORP. | ||
Patents | 10,071,977; 10,149,829; 9,060,995; 9,539,234; 9,549,913; 9,730,910; 9,855,241; RE46,604 | ||
Attorneys | Gregory F. Fischer | ||
Firms | Gordon Rees Scully Mansukhani LLP | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Apotex Inc.
Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-05-07 | 1 | Complaint | of Vanda’s U.S. Patent Nos. RE46,604 (“the RE604 patent”); 9,060,995 (“the ’995 patent”); 9,539,234 (… V. THE PATENTS-IN-SUIT (U.S. PATENT NOS. RE46,604; 9,060,995; 9,539,234; 9,549,913;… U.S. Patent No. 9,060,995 41. Vanda is the owner… (“the ’234 patent”); 9,549,913 (“the ’913 patent”); 9,730,910 (“the ’910 patent”); and 9,855,241 (“the…“the ’241 patent”) (collectively “the Asserted Patents”), which, in relevant part, generally relate to | External link to document |
2019-12-03 | 118 | Notice of Service | U.S. Patent No. 10,071,977; (2) Defendants' Amended Invalidity Contentions Regarding U.S. Patent No. 10,149,829… 7 May 2018 1:18-cv-00689 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
2019-12-19 | 120 | Notice of Service | Supplemental Infringement Contentions for U.S. Patent No. 10,071,977 filed by Vanda Pharmaceuticals Inc..(Fahnestock… 7 May 2018 1:18-cv-00689 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |